Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04487704 | Camrelizumab Utilization on Patients With Advanced Liver Cancer | unknown | N/A | 1,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353894 |
| Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers |
| unknown |
| Phase 1 |
| 27 |
| Genoscience PharmaINDUSTRY |
| 1 |
| Apr 29, 2022 |
| clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05339581 | IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation(iPLENTY-pvtt) | unknown | N/A | 78 | RenJi HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05171439 | Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples | unknown | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03958019 | Rehabilitation Strategies Following Oesophagogastric and Hepatopancreaticobiliary Cancer(RESTORE II) | unknown | N/A | 120 | University of Dublin, Trinity CollegeOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT03223818 | The Impact of Fast-track Perioperative Program After Liver Resection in Hong Kong Chinese Patients | unknown | N/A | 94 | Chinese University of Hong KongOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05024539 | Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma | unknown | — | 300 | Shujun YangOTHER_GOV | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05311319 | HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04182386 | Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization | unknown | — | 300 | Karolinska University HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04943679 | Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC | unknown | — | 15 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05200221 | A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice | unknown | — | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05205629 | A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05286099 | The Surveillance of Hepatocellular Carcinoma | unknown | — | 100 | Chinese PLA General HospitalOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05281926 | A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients | unknown | Phase 1 | 10 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05282433 | Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 45 | Zhongnan HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05277675 | Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)(RANT) | unknown | N/A | 160 | Southwest Hospital, ChinaOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05278195 | Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers(CHANCEsub) | unknown | — | 300 | Zhongda HospitalOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04825470 | Liver Transplantation for Unresectable GIST Liver Metastases(TRANSGIST) | unknown | N/A | 50 | Hospital Universitario Virgen de la ArrixacaOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05270642 | Plan for Microwave Thermal Field | unknown | N/A | 5 | Chinese PLA General HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03322280 | TACE Combined With Iodine-125 Seeds Implantation for HCC | unknown | N/A | 270 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247996 | TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | N/A | 98 | The Central Hospital of Lishui CityOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT05242237 | Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform | unknown | — | 300 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05242757 | Clinical Study of MAK Immune Cells in the Treatment of PHC | unknown | N/A | 12 | Zhongnan HospitalOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05240404 | Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma | unknown | Phase 2 | 116 | Xiangya Hospital of Central South UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05240690 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | unknown | Phase 1 | 27 | Zhou FuxiangOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02009176 | Laparoscope Anatomical and Aon-anatomical Hepatectomy | unknown | N/A | 110 | Shuguo Zheng, MDOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05118451 | A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLC | unknown | N/A | 420 | Zhujiang HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05233358 | HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure | unknown | N/A | 176 | The Central Hospital of Lishui CityOTHER | 0 | Feb 10, 2022 | clinicaltrials |
| NCT05213637 | Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 430 | Chinese PLA General HospitalOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05160740 | Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer(ICGMFITinPLC) | unknown | N/A | 348 | Zhujiang HospitalOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 72 | National Taiwan University HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05113290 | Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | unknown | Phase 4 | 66 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05162898 | Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma. | unknown | N/A | 90 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 27, 2022 | clinicaltrials |
| NCT03067493 | RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial(RAMEC) | unknown | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05202015 | Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study(HepCaSt) | unknown | — | 150 | Charite University, Berlin, GermanyOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT02192671 | HR Versus RFA for HCC in Patients With PHT(HR-HCC/PHT) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT02203409 | Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy | unknown | — | 30 | Shuguo Zheng, MDOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03973112 | A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 123 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT04981665 | A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04715321 | CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma | unknown | — | 120 | Sun Yat-sen UniversityOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05171309 | Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | unknown | Phase 2 | 35 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05170282 | Deep Learning Magnetic Resonance Imaging Radiomics for Diagnostic Value of Hepatic Tumors in Infants | unknown | — | 200 | West China HospitalOTHER | 1 | Dec 27, 2021 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2022source: clinicaltrials